1. Medtech Insight
  2. >>Business

Adagio Closes $42.5M Financing To Develop Ablation Technologies

 
• By Reed Miller

The series E financing will support the ongoing US trial of Adagio’s iCLAS cardiac cryoablation system and development of Adagio's pulsed field cryoablation technology while the company continues to commercialize iCLAS outside the US.

Venture Capital Concept on the Mechanism of Metal Gears.
• Source: shutterstock.com

Southern California-based cardiac ablation technology developer Adagio Medical, Inc. closed a $42.5m series E equity financing on 12 November.

The new funds will support the ongoing investigational device exemption (IDE) trial of Adagio’s intelligent continuous lesion ablation cryoablation...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business